301 BINNEY STREET, CAMBRIDGE, MA
Merger Agreement Announcement Conference Call, Investor Presentation
Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
Investor Presentation
Other Events
News
Material Contracts
News, Material Contracts
Q3
Amended Annual Report
Q2
Q1
FY 2024
Prospectus Filed Pursuant to Rule 425
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
Definitive Merger Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload